CEBPA and hepatocellular carcinoma: Therefore, ACSL4 and its upstream regulator CEBPA serve as promising prognostic indicators and potential therapeutic targets for TACE treatment in HCC, emphasizing the need for further research to fully understand the implications of this pathway for HCC management.